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What are the novel findings of this work?
The performance of combined first-trimester screening in
predicting early-onset and preterm pre-eclampsia (PE) is
similar when serum levels of pregnancy-associated plasma
protein-A and placental growth factor are measured
before or after 11 weeks’ gestation.
What are the clinical implications of this work?
Measurement of serum biomarkers for both PE and
aneuploidy screening before the first-trimester scan
permits risk calculation for both screening tests at the
time of the scan without compromising PE screening
performance.
ABSTRACT
Objectives To compare the ability of first-trimester
combined screening for pre-eclampsia (PE) to predict
early-onset and preterm PE when pregnancy-associated
plasma protein-A (PAPP-A) and placental growth factor
(PlGF) were assessed before vs after 11 weeks’ gestation.
Methods This was a secondary analysis of a prospective
cohort study of singleton pregnancies undergoing rou-
tine first-trimester screening conducted at Vall d’Hebron
University Hospital, Barcelona, Spain, between October
2015 and September 2017. Demographic characteris-
tics, obstetric history, maternal history and biophysical
markers (mean uterine artery pulsatility index and mean
arterial blood pressure (MAP)) were recorded at the
first-trimester scan (at 11 + 0 to 13 + 6 weeks’ gesta-
tion). Maternal serum concentrations of PAPP-A and
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PlGF were assessed from the routine first-trimester blood
test (at 8 + 0 to 13 + 6 weeks). Women were classified
into two groups depending on whether serum biomark-
ers were assessed at 8 + 0 to 10 + 6 weeks or at 11 + 0
to 13 + 6 weeks. Probability scores for early-onset and
preterm PE were calculated by using two different algo-
rithms: the multivariate Gaussian-distribution model and
The Fetal Medicine Foundation (FMF) competing-risks
model. Receiver-operating-characteristics (ROC) curves
were produced and detection rates at fixed 5% and 10%
false-positive rates were computed to compare the perfor-
mance of these algorithms when PAPP-A and PlGF were
assessed before vs after 11 weeks.
Results Of the 2641 women included, serum biomarkers
were assessed before 11 weeks in 1675 (63.4%) and at or
after 11 weeks in 966 (36.6%). Of these, 90 (3.4%)
women developed PE, including 11 (0.4%) cases of
early-onset PE and 30 (1.1%) of preterm PE. Five (45.5%)
cases of early-onset and 16 (53.3%) of preterm PE were
identified in the group in which serum biomarkers were
assessed at 8 + 0 to 10 + 6 weeks and six (54.5%) cases
of early-onset and 14 (46.7%) of preterm PE in the group
in which serum biomarkers were assessed at 11 + 0 to
13 + 6 weeks. In the prediction of early-onset and preterm
PE using the Gaussian algorithm, no differences were
observed between the areas under the ROC curves (AUCs)
when PAPP-A and PlGF were measured before or after
11 weeks. In the prediction of early-onset and preterm PE
using the FMF algorithm, no differences were observed
between AUCs for any of the combinations used for risk
calculation when the serum biomarkers were obtained
before vs after 11 weeks, except for the combination of
PAPP-A and MAP, which showed a greater AUC for the
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prediction of early-onset PE when PAPP-A was measured
at or after 11 weeks.
Conclusions The prediction of early-onset and preterm
PE is similar when serum biomarkers are measured
before or after 11 weeks. This allows the use of a
two-step approach for PE risk assessment that permits
immediate risk calculation at the time of the first-trimester
scan. © 2020 The Authors. Ultrasound in Obstetrics &
Gynecology published by John Wiley & Sons Ltd on
behalf of International Society of Ultrasound in Obstetrics
and Gynecology.
INTRODUCTION
Pre-eclampsia (PE) occurs in approximately 2–8% of
pregnancies1. It is the primary cause of maternal
admission to the intensive care unit and is responsible
for approximately 15% of all pregnancy-related deaths in
developed countries2,3. In recent years, several studies
published by The Fetal Medicine Foundation (FMF)
have shown that their algorithm constructed by a
combination of maternal history and biochemical and
biophysical markers in the first trimester of pregnancy can
effectively predict early-onset and preterm PE4, allowing
commencement of acetylsalicylic acid (ASA) before
16 weeks’ gestation, which has proved to significantly
reduce the risk of developing PE5.
Recently, our group participated in the development of
a new first-trimester Gaussian model constructed using
the same variables as in the FMF algorithm, which also
has a good performance in the prediction of early-onset
PE6. In both studies4,6, maternal characteristics and
biophysical markers were assessed at the time of the
first-trimester ultrasound examination (between 11 + 0
and 13 + 6 weeks). However, serum biomarkers were
assessed between 11 + 0 and 13 + 6 weeks in the FMF
study while in our study they were assessed between
8 + 0 and 13 + 6 weeks, preferably before the ultrasound
assessment, using a two-step approach. The reason for
assessing serum biomarkers early in the first trimester was
that the blood samples were drawn at the time of routine
first-trimester aneuploidy screening, which is usually done
before the first-trimester scan since the performance of
first-trimester biochemical screening for trisomy 21 is best
done at 9–10 weeks7,8. Placental growth factor (PlGF)
is the most valuable biomarker used in both algorithms.
Even though PlGF has been shown to have excellent
precision and reliability from 5 + 0 weeks onwards for
discriminating between PE and normal pregnancies9, a
recent study found that its predictive capacity for PE
increases after 11 weeks10. Therefore, it is reasonable to
believe that the precision of these algorithms may drop
when PlGF is measured before 11 weeks; however, the
performance of these algorithms in the early and late
first trimester has not been compared. The aim of this
study was to evaluate the performance of the FMF and
the Gaussian algorithms in predicting early-onset and
preterm PE when pregnancy-associated plasma protein-A
(PAPP-A) and PlGF were assessed before, compared with
after, 11 weeks.
METHODS
This was a secondary analysis of data from the population
that participated in the development of the first-trimester
Gaussian algorithm to predict early-onset PE6. That
prospective cohort study was conducted at Vall d’Hebron
University Hospital, Barcelona, Spain, from October
2015 to September 2017. The local ethics committee
(CEIC-VHIR PR(AMI)265/2018) approved the study
protocol. A total of 3777 unselected singleton pregnant
women attending for their routine first-trimester scan
(from 11 + 0 to 13 + 6 weeks) were invited to participate,
of whom 2946 agreed and provided written informed
consent. Of these, 305 (10.4%) participants were
excluded owing to missing outcome data (n = 86), major
fetal defects or chromosomopathies (n = 13), miscarriage
or fetal death before 24 weeks (n = 15) or insufficient
remaining blood sample to measure PlGF (n = 191). None
of the remaining 2641 participants had received ASA at
any time during their pregnancy.
After gestational age (GA) had been confirmed
by fetal crown–rump length measurement during the
scan11, demographic characteristics, obstetric history,
maternal history, biophysical markers and biochemical
markers were recorded in an electronic database. In
all participants, transabdominal mean uterine artery
pulsatility index (UtA-PI)12 and mean arterial blood
pressure (MAP) were assessed during the first-trimester
scan at 11 + 0 to 13 + 6 weeks. Maternal blood samples
were analyzed to establish the serum concentrations of
PAPP-A and PlGF. One sample was obtained from each
woman during the routine first-trimester blood test for
aneuploidy screening, at 8 + 0 to 13 + 6 weeks. Maternal
serum levels of PAPP-A (mU/L) and PlGF (pg/mL)
were determined by fully automated Elecsys assays for
PAPP-A and PlGF on an immunoassay platform (Cobas e
analyzers; Roche Diagnostics, Rotkreuz, Switzerland). As
PAPP-A and PlGF values change with GA, they were
transformed to multiples of the median to be used in risk
assessment6.
In all patients, blood pressure (BP) was measured
at 11 + 0 to 13 + 6 weeks by a nurse using an
automatic BP measurement device (Microlife WatchBP
Home; Microlife Corporation, Taipei, Taiwan); a single
measurement was obtained in one arm (right or left)
after a 5-min rest while the woman was seated. MAP
was calculated as: diastolic BP + (systolic BP – diastolic
BP)/3.
PE was defined according to the guidelines of the
International Society for the Study of Hypertension in
Pregnancy as systolic BP ≥ 140 mmHg and/or diastolic BP
≥ 90 mmHg confirmed by repeat measurements over a few
hours, developing after 20 weeks’ gestation in a previously
normotensive woman, accompanied by proteinuria of
≥ 300 mg per 24 h or a spot urine protein-to-creatinine
ratio ≥ 0.3 mg/mg or dipstick urinalysis ≥ 1+ when a
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quantitative method was not available13. Early-onset and
preterm PE were defined as PE necessitating delivery
before 34 weeks and before 37 weeks, respectively.
Women were classified into two groups according to
whether the blood sample for biomarker assessment
was drawn before or after 11 weeks’ gestation. We
then coded the variables required for the prediction
formulae according to the description provided in
the articles and calculated the probability score for
early-onset PE using two different algorithms: the
multivariate Gaussian-distribution model and the FMF
competing-risks model4,6.
Receiver-operating-characteristics (ROC) curves were
produced and detection rates at fixed 5% and 10%
false-positive rates (FPR) were computed for all com-
binations of markers involved in the risk assessment, to
compare the performance of the two algorithms for pre-
dicting early-onset and preterm PE when PAPP-A and
PlGF were measured before and after 11 weeks14.
Statistical analysis
Rcmdr package for R version 2.3-1 software (The R
Foundation, Vienna, Austria) was used for statistical
analysis. Differences in categorical data between the
groups were assessed using the χ-square or Fisher’s exact
test, as appropriate, and are reported as n (%). Differences
in continuous variables between the groups were assessed
using the Mann–Whitney U-test and are reported as
median (interquartile range). Statistical significance was
set at P < 0.05.
RESULTS
PAPP-A and PlGF were assessed before 11 weeks in 1675
(63.4%) of the 2641 women, and at or after 11 weeks
in 966 (36.6%). Ninety (3.4%) women developed PE,
including 30 (1.1%) cases of preterm PE and 11 (0.4%)
of early-onset PE. Five (45.5%) cases of early-onset
and 16 (53.3%) of preterm PE were identified in
the group in which serum biomarkers were assessed
at 8 + 0 to 10 + 6 weeks and six (54.5%) cases of
early-onset and 14 (46.7%) of preterm PE in the group
in which serum biomarkers were assessed at 11 + 0 to
13 + 6 weeks.
Baseline characteristics of the study population were
compared between the two groups (assessment of
biochemical markers before 11 vs at or after 11 weeks)
and are shown in Table 1. In women who developed
early-onset PE, no significant differences were observed
between the two groups apart from GA at the time of
PAPP-A and PlGF assessment. In women who developed
preterm PE, PAPP-A and PlGF levels and the GA at
their measurement were significantly different between the
two groups. When non-affected women were evaluated,
significant differences were observed between the two
groups in ethnicity, smoking status, obstetric history,
PAPP-A and PlGF levels and GA at their measurement,
UtA-PI and GA at ultrasound assessment.
In the prediction of early-onset PE and preterm PE
using the Gaussian algorithm, no significant differences
were observed in the areas under the ROC curves
(AUCs) for any of the combinations of markers evaluated
when the biochemical markers were assessed at 8 + 0
to 10 + 6 weeks compared with 11 + 0 to 13 + 6 weeks.
Additionally, no substantial differences were observed
in the detection rates at fixed 5% and 10% FPRs. The
predictive capacity and detection rates in screening for
early-onset and preterm PE by the markers involved in
the Gaussian algorithm are shown in Tables 2 and 3,
respectively.
In the prediction of early-onset PE using the FMF
algorithm, no significant differences were observed in the
AUCs for any of the combinations of markers evaluated
when the biochemical markers were assessed before vs
after 11 weeks, except for the combination of PAPP-A
and MAP, which showed a greater AUC when PAPP-A
was measured at or after 11 weeks. However, despite
this significant difference, no substantial differences were
observed in the detection rates at fixed 5% and 10% FPRs.
The predictive capacity and detection rates in screening
for early-onset PE using the FMF algorithm are shown in
Table 4.
In the prediction of preterm PE using the FMF
algorithm, no significant differences were observed in the
AUCs for any of the combinations of markers evaluated
when PAPP-A and PlGF were assessed before, compared
with at or after, 11 weeks. In addition, no substantial
differences were observed in the detection rates at fixed
5% and 10% FPRs. The predictive capacity and detection
rates in screening for preterm PE using the FMF algorithm
are shown in Table 5.
DISCUSSION
This study provides evidence that multimarker algorithms
have a similar performance in predicting early-onset and
preterm PE when PlGF and PAPP-A are measured at 8 + 0
to 10 + 6 weeks or at 11 + 0 to 13 + 6 weeks’ gestation.
The timing of measurement of the serum biomarkers
did not affect the performance of the Gaussian or the
FMF algorithm in predicting preterm PE when PAPP-A
or PlGF was used alone or in combination with other
markers. However, for the FMF model, the combination
of PAPP-A and MAP had a lower predictive capacity
for early-onset PE when PAPP-A was measured before
11 weeks compared with at or after 11 weeks, which is
probably due to the low number of cases with early-onset
PE.
A previous study evaluating the external validity of the
available algorithms for the first-trimester prediction of PE
found that they underperformed if applied to an external
population15. Additionally, PlGF seems to better identify
patients at risk for PE when measured after 11 weeks10.
Nonetheless, the performance of combined screening for
early-onset and preterm PE with biomarkers assessed
at different points in gestation has not been assessed
previously.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 84–90.
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Our results have important clinical implications. They
show that a two-step approach to first-trimester PE screen-
ing (combination of serum markers (PAPP-A and PlGF)
measured at 8–10 weeks and biophysical markers (MAP
and UtA-PI) measured at 11–13 weeks) is feasible, since
its performance for predicting early-onset and preterm
PE does not deteriorate when serum biomarker levels
are measured before 11 weeks. Additionally, a two-step
approach allows PE screening results to be provided imme-
diately after the first-trimester ultrasound assessment.
The main limitation of this study is the low number
of cases with early-onset PE and the relatively low
Table 1 Baseline characteristics and biophysical and biochemical measurements in women who developed early-onset (before 34 weeks)
pre-eclampsia (PE), those who developed preterm (before 37 weeks) PE and those who did not develop PE before 37 weeks’ gestation,
according to whether pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) were measured before or after
11 weeks
PE before 34 + 0 weeks (n = 11) PE before 37 + 0 weeks (n = 30) No PE before 37 + 0 weeks (n = 2611)
Biochemical markers measured at: Biochemical markers measured at: Biochemical markers measured at:
Parameter
8 + 0 to
10 + 6 weeks
(n = 5)
11 + 0 to
13 + 6 weeks
(n = 6) P
8 + 0 to
10 + 6 weeks
(n = 16)
11 + 0 to
13 + 6 weeks
(n = 14) P
8 + 0 to
10 + 6 weeks
(n = 1659)
11 + 0 to
13 + 6 weeks



























Ethnicity 0.455 0.734 < 0.001
White 4 (80.0) 6 (100) 13 (81.3) 12 (85.7) 1441 (86.9) 768 (80.7) < 0.001
Black 0 (0) 0 (0) 0 (0) 1 (7.1) 34 (2.0) 37 (3.9) 0.008
Mixed 1 (20.0) 0 (0) 2 (12.5) 0 (0) 109 (6.6) 100 (10.5) < 0.001
Asian 0 (0) 0 (0) 1 (6.3) 1 (7.1) 40 (2.4) 23 (2.4) 1.0
South-East Asian 0 (0) 0 (0) 0 (0) 0 (0) 35 (2.1) 24 (2.5) 0.497
Smoker 1 (20.0) 0 (0) 0.455 1 (6.3) 2 (14.3) 0.586 214 (12.9) 95 (10.0) 0.028
ART 0 (0) 1 (16.7) 1.0 0 (0) 2 (14.3) 0.209 60 (3.6) 33 (3.5) 0.731
Insemination 0 (0) 1 (16.7) 0 (0) 1 (7.1) 10 (0.6) 6 (0.6)
IVF 0 (0) 0 (0) 0 (0) 0 (0) 31 (1.9) 21 (2.2)
IVF with egg donation 0 (0) 0 (0) 0 (0) 1 (7.1) 19 (1.1) 6 (0.6)
Medical history 1.0 1.0 0.695
Chronic hypertension 2 (40.0) 1 (16.7) 3 (18.8) 2 (14.3) 15 (0.9) 9 (0.9)
Diabetes mellitus 0 (0) 0 (0) 1 (6.3) 0 (0) 25 (1.5) 10 (1.1)
Autoimmune disease 0 (0) 0 (0) 1 (6.3) 2 (14.3) 63 (3.8) 42 (4.4)
APS 0 (0) 0 (0) 1 (6.3) 0 (0) 4 (0.2) 4 (0.4)
Obstetric history 0.250 0.484 0.002
Nulliparous 0 (0) 2 (33.3) 6 (37.5) 7 (50.0) 813 (49.0) 406 (42.6) 0.002
Previous PE 1 (20.0) 1 (16.7) 4 (25.0) 1 (7.1) 16 (1.0) 14 (1.5) 0.256
Previous FGR 0 (0) 0 (0) 0 (0) 1 (7.1) 18 (1.1) 5 (0.5) 0.191
Biophysical variable







































































































































Data are reported as median (interquartile range) or n (%). APS, antiphospholipid syndrome; ART, assisted reproductive technology; BMI,
body mass index; FGR, fetal growth restriction; GA, gestational age; IVF, in-vitro fertilization; MAP, mean arterial pressure; MoM,
multiples of the median; UtA-PI, uterine artery pulsatility index; US, ultrasound.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 84–90.
on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
88 Mendoza et al.
number of cases with preterm PE; thus, our results
should be considered with caution and validated in
a larger cohort to ascertain whether the timing of
biomarker assessment affects the screening performance
of multimarker first-trimester algorithms for the detection
of early-onset PE. Furthermore, there were statistically
significant differences in baseline characteristics (ethnicity,
smoking status, obstetric history, UtA-PI and GA at
ultrasound assessment) between the two cohorts of
unaffected women, the most important being that the
first-trimester scan was performed slightly later in women
in whom serum biomarkers were measured at or after
11 weeks (median GA, 12.9 vs 12.6 weeks). Nevertheless,
this difference is small and probably not clinically
significant. Finally, MAP was assessed by a single BP
measurement in one arm, which has been shown to
Table 2 Detection rate (DR) and area under receiver-operating-characteristics curve (AUC) for prediction of pre-eclampsia before 34 weeks’
gestation by Gaussian model, according to whether pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF)
were measured before or after 11 weeks
8 + 0 to 10 + 6 weeks (n = 5) 11 + 0 to 13 + 6 weeks (n = 6)
DR (% (95% CI)) at: DR (% (95% CI)) at:
Method of screening AUC (95% CI) 5% FPR 10% FPR AUC (95% CI) 5% FPR 10% FPR P*
A-priori risk plus:
MAP 0.746 (0.540–0.952) 40.0 (0–80.0) 40.0 (0–80.0) 0.887 (0.818–0.956) 33.3 (0–66.7) 50.0 (0–83.3) 0.364
UtA-PI 0.863 (0.700–1.000) 60.0 (20.0–100) 60.0 (20.0–100) 0.812 (0.649–0.974) 33.3 (0–66.7) 50.0 (16.7–83.3) 0.733
PAPP-A 0.615 (0.279–0.951) 20.0 (0–60.0) 40.0 (0–80.0) 0.803 (0.626–0.980) 33.3 (0–66.7) 50.0 (0–83.3) 0.277
PlGF 0.829 (0.732–0.927) 40.0 (0–80.0) 40.0 (0–80.0) 0.712 (0.479–0.945) 33.3 (0–66.7) 33.3 (0–66.7) 0.478
PlGF + UtA-PI 0.923 (0.844–1.000) 60.0 (20.0–100) 60.0 (20.0–100) 0.841 (0.687–0.995) 50.0 (16.7–83.3) 50.0 (16.7–83.3) 0.530
MAP + PlGF 0.864 (0.746–0.982) 40.0 (0–80.0) 40.0 (0–80.0) 0.936 (0.894–0.978) 33.3 (0–66.7) 66.7 (33.3–100) 0.566
MAP + UtA-PI 0.901 (0.793–1.000) 60.0 (20.0–100) 60.0 (20.0–100) 0.916 (0.822–1.000) 66.7 (33.3–100) 66.7 (33.3–100) 0.901
PAPP-A + PlGF 0.790 (0.684–0.896) 20.0 (0–60.0) 40.0 (0–80.0) 0.751 (0.556–0.946) 33.3 (0–66.7) 50.0 (16.7–83.3) 0.816
MAP + PAPP-A 0.744 (0.542–0.947) 40.0 (0–80.0) 40.0 (0–80.0) 0.910 (0.853–0.968) 33.3 (0–66.7) 66.7 (16.7–100) 0.272
UtA-PI + PAPP-A 0.849 (0.666–1.000) 60.0 (20.0–100) 60.0 (20.0–100) 0.846 (0.707–0.986) 50.0 (16.7–83.3) 50.0 (16.7–83.3) 0.984
MAP + UtA-PI + PAPP-A 0.891 (0.772–1.000) 60.0 (20.0–100) 60.0 (20.0–100) 0.929 (0.850–1.000) 66.7 (33.3–100) 66.7 (33.3–100) 0.752
MAP + UtA-PI + PlGF 0.943 (0.881–1.000) 60.0 (20.0–100) 80.0 (20.0–100) 0.958 (0.925–0.990) 50.0 (16.7–83.3) 83.3 (50.0–100) 0.871
MAP + PAPP-A + PlGF 0.838 (0.709–0.967) 40.0 (0–80.0) 40.0 (0–80.0) 0.930 (0.889–0.971) 33.3 (0–73.9) 66.7 (16.7–100) 0.488
UtA-PI + PlGF + PAPP-A 0.912 (0.820–1.000) 60.0 (20.0–100) 60.0 (20.0–100) 0.842 (0.689–0.995) 50.0 (16.7–83.3) 50.0 (16.7–83.3) 0.600
MAP + UtA-PI + PlGF + PAPP-A 0.935 (0.866–1.000) 60.0 (20.0–100) 80.0 (20.0–100) 0.950 (0.915–0.986) 50.0 (16.7–83.3) 83.3 (50.0–100) 0.879
*Comparison between AUCs was by two-tailed P-value. FPR, false-positive rate; MAP, mean arterial pressure; UtA-PI, uterine artery
pulsatility index.
Table 3 Detection rate (DR) and area under receiver-operating-characteristics curve (AUC) for prediction of pre-eclampsia before 37 weeks’
gestation by Gaussian model, according to whether pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF)
were measured before or after 11 weeks
8 + 0 to 10 + 6 weeks (n = 16) 11 + 0 to 13 + 6 weeks (n = 14)
DR (% (95% CI)) at: DR (% (95% CI)) at:
Method of screening AUC (95% CI) 5% FPR 10% FPR AUC (95% CI) 5% FPR 10% FPR P*
A-priori risk plus:
MAP 0.757 (0.647–0.866) 25.0 (6.3–43.8) 37.5 (18.8–68.8) 0.736 (0.590–0.883) 28.6 (7.1–50.0) 35.7 (7.1–64.3) 0.841
UtA-PI 0.724 (0.564–0.884) 43.8 (18.8–68.8) 50.0 (25.0–75.0) 0.688 (0.541–0.835) 28.6 (7.1–50.0) 35.7 (14.3–64.3) 0.738
PAPP-A 0.678 (0.520–0.835) 25.0 (6.3–50.0) 43.8 (18.8–68.8) 0.748 (0.621–0.875) 14.3 (0–35.7) 35.7 (7.1–64.3) 0.511
PlGF 0.719 (0.593–0.846) 25.0 (6.3–43.8) 25.0 (6.3–43.8) 0.712 (0.569–0.855) 35.7 (14.3–64.3) 35.7 (14.3–64.3) 0.948
PlGF + UtA-PI 0.746 (0.589–0.903) 37.5 (12.5–62.5) 43.8 (18.8–68.8) 0.719 (0.571–0.866) 42.9 (14.3–71.4) 42.9 (14.3–71.4) 0.798
MAP + PlGF 0.802 (0.717–0.888) 25.0 (6.3–50.0) 31.3 (12.5–56.3) 0.799 (0.654–0.944) 28.6 (7.1–57.1) 57.1 (28.6–85.7) 0.976
MAP + UtA-PI 0.798 (0.701–0.894) 31.3 (12.5–56.3) 31.3 (12.5–56.3) 0.765 (0.604–0.926) 42.9 (14.3–71.4) 50.0 (21.4–78.6) 0.743
PAPP-A + PlGF 0.723 (0.595–0.851) 25.0 (6.3–43.8) 25.0 (6.3–50.0) 0.777 (0.648–0.906) 35.7 (14.3–64.3) 42.9 (21.4–71.4) 0.636
MAP + PAPP-A 0.780 (0.678–0.883) 37.5 (18.8–62.5) 43.8 (18.8–68.8) 0.765 (0.620–0.910) 28.6 (7.1–50.0) 42.9 (14.3–71.4) 0.883
UtA-PI + PAPP-A 0.744 (0.585–0.902) 43.8 (18.8–68.8) 50.0 (25.0–75.0) 0.709 (0.565–0.853) 21.4 (7.1–50.0) 35.7 (14.3–64.3) 0.742
MAP + UtA-PI + PAPP-A 0.815 (0.720–0.909) 31.3 (12.5–56.3) 37.5 (12.5–62.5) 0.779 (0.619–0.938) 42.9 (21.4–71.4) 50.0 (28.4–78.6) 0.714
MAP + UtA-PI + PlGF 0.804 (0.687–0.920) 31.3 (12.5–56.3) 37.5 (12.5–62.5) 0.793 (0.636–0.950) 42.9 (21.4–71.4) 50.0 (21.4–78.6) 0.911
MAP + PAPP-A + PlGF 0.803 (0.721–0.885) 31.3 (12.5–62.5) 37.5 (12.5–62.5) 0.801 (0.660–0.941) 28.6 (7.1–57.1) 50.0 (21.4–78.6) 0.984
UtA-PI + PlGF + PAPP-A 0.749 (0.592–0.906) 37.5 (12.5–62.5) 43.8 (18.8–68.8) 0.722 (0.575–0.969) 42.9 (14.3–71.4) 42.9 (14.3–71.4) 0.798
MAP + UtA-PI + PlGF + PAPP-A 0.772 (0.639–0.904) 31.3 (12.5–56.3) 50.0 (25.0–75.0) 0.795 (0.640–0.950) 35.7 (14.3–64.3) 64.3 (35.7–85.7) 0.803
*Comparison between AUCs was by two-tailed P-value. FPR, false-positive rate; MAP, mean arterial pressure; UtA-PI, uterine artery
pulsatility index.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 84–90.
on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
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give significantly higher values than does assessment
using the average of two measurements in both arms16.
Since the latter is the methodology used in the FMF
algorithm, it could have influenced its performance to
predict PE in our cohort. However, the inaccuracies
that might have resulted from the use of a single
measurement for PE risk assessment by the FMF algorithm
would have affected all participants similarly, thereby
rendering the groups still comparable for the purpose of
this study.
In conclusion, the Gaussian and the FMF algorithms
have a similar performance in predicting early-onset PE
and preterm PE when PAPP-A and PlGF are measured
before or after 11 weeks, allowing the use of a two-step
risk assessment for PE. This approach allows immediate
PE risk calculation at the time of the first-trimester scan.
Table 4 Detection rate (DR) and area under receiver-operating-characteristics curve (AUC) for prediction of pre-eclampsia before 34 weeks’
gestation by Fetal Medicine Foundation competing-risks model, according to whether pregnancy-associated plasma protein-A (PAPP-A) and
placental growth factor (PlGF) were measured before or after 11 weeks
8 + 0 to 10 + 6 weeks (n = 5) 11 + 0 to 13 + 6 weeks (n = 6)
DR (% (95% CI)) at: DR (% (95% CI)) at:
Method of screening AUC (95% CI) 5% FPR 10% FPR AUC (95% CI) 5% FPR 10% FPR P*
A-priori risk plus:
MAP 0.655 (0.377–0.934) 40.0 (0–80.0) 40.0 (0–80.0) 0.844 (0.778–0.909) 16.7 (0–50.0) 16.7 (0–50.0) 0.259
UtA-PI 0.744 (0.478–1.000) 40.0 (0–80.0) 40.0 (0–80.0) 0.809 (0.610–1.000) 33.3 (0–66.7) 66.7 (33.3–100) 0.697
PAPP-A 0.472 (0.098–0.846) 40.0 (0–80.0) 40.0 (0–80.0) 0.750 (0.547–0.954) 33.3 (0–66.7) 33.3 (0–66.7) 0.105
PlGF 0.742 (0.540–0.944) 20.0 (0–60.0) 40.0 (0–80.0) 0.752 (0.509–0.995) 33.3 (0–66.7) 33.3 (0–66.7) 0.954
PlGF + UtA-PI 0.856 (0.716–0.995) 40.0 (0–80.0) 60.0 (20.0–100) 0.838 (0.622–1.000) 50.0 (16.3–83.3) 66.7 (16.7–100) 0.903
MAP + PlGF 0.801 (0.630–0.972) 40.0 (0–80.0) 40.0 (0–80.0) 0.905 (0.833–0.977) 33.3 (0–83.3) 50.0 (16.7–83.3) 0.473
MAP + UtA-PI 0.812 (0.623–1.000) 40.0 (0–80.0) 40.0 (0–80.0) 0.914 (0.838–0.990) 50.0 (16.7–83.3) 66.7 (16.7–100) 0.470
PAPP-A + PlGF 0.723 (0.517–0.930) 20.0 (0–60.0) 40.0 (0–80.0) 0.769 (0.540–0.997) 33.3 (0–66.7) 33.3 (0–83.3) 0.790
MAP + PAPP-A 0.356 (0.075–0.638) 40.0 (0–80.0) 40.0 (0–80.0) 0.892 (0.844–0.941) 16.7 (0–50.0) 50.0 (16.7–83.3) < 0.001
UtA-PI + PAPP-A 0.719 (0.426–1.000) 40.0 (0–80.0) 60.0 (20.0–100) 0.855 (0.697–1.000) 50.0 (0–83.3) 66.7 (33.3–100) 0.403
MAP + UtA-PI + PAPP-A 0.790 (0.580–0.999) 40.0 (0–80.0) 40.0 (0–80.0) 0.937 (0.881–0.992) 50.0 (16.7–83.3) 66.7 (33.3–100) 0.292
MAP + UtA-PI + PlGF 0.886 (0.770–1.000) 40.0 (0–80.0) 60.0 (20.0–100) 0.954 (0.905–1.000) 83.3 (33.3–100) 83.3 (50.0–100) 0.552
MAP + PAPP-A + PlGF 0.789 (0.617–0.961) 40.0 (0–80.0) 40.0 (0–80.0) 0.916 (0.853–0.978) 50.0 (0–83.3) 50.0 (16.7–100) 0.379
UtA-PI + PlGF + PAPP-A 0.847 (0.700–0.994) 40.0 (0–80.0) 60.0 (20.0–100) 0.847 (0.642–1.000) 50.0 (16.7–83.3) 66.7 (16.7–100) 1.00
MAP + UtA-PI + PlGF + PAPP-A 0.926 (0.838–1.000) 60.0 (20.0–100) 80.0 (40.0–100) 0.967 (0.944–0.989) 66.7 (33.3–100) 100 (100–100) 0.669
*Comparison between AUCs was by two-tailed P-value. FPR, false-positive rate; MAP, mean arterial pressure; UtA-PI, uterine artery
pulsatility index.
Table 5 Detection rate (DR) and area under receiver-operating-characteristics curve (AUC) for prediction of pre-eclampsia before 37 weeks’
gestation by Fetal Medicine Foundation competing-risks model, according to whether pregnancy-associated plasma protein-A (PAPP-A) and
placental growth factor (PlGF) were measured before or after 11 weeks
8 + 0 to 10 + 6 weeks (n = 16) 11 + 0 to 13 + 6 weeks (n = 14)
DR (% (95% CI)) at: DR (% (95% CI)) at:
Method of screening AUC (95% CI) 5% FPR 10% FPR AUC (95% CI) 5% FPR 10% FPR P*
A-priori risk plus:
MAP 0.722 (0.604–0.840) 31.3 (12.5–56.3) 31.3 (12.5–56.3) 0.734 (0.593–0.875) 21.4 (0–42.9) 28.6 (7.1–50.0) 0.910
UtA-PI 0.749 (0.617–0.882) 18.8 (0–37.7) 43.8 (25.0–68.8) 0.721 (0.566–0.876) 21.4 (0–42.9) 50.0 (28.4–78.6) 0.791
PAPP-A 0.689 (0.529–0.850) 12.5 (0–37.5) 31.3 (12.5–56.3) 0.722 (0.592–0.853) 21.4 (0–42.9) 35.7 (14.3–57.1) 0.759
PlGF 0.738 (0.633–0.842) 12.5 (0–37.5) 31.3 (12.5–56.3) 0.737 (0.593–0.880) 35.7 (14.3–57.1) 35.7 (14.3–57.1) 0.992
PlGF + UtA-PI 0.746 (0.637–0.855) 18.8 (0–43.8) 37.5 (18.8–62.5) 0.745 (0.603–0.886) 42.9 (21.4–71.4) 50.0 (21.4–78.6) 0.992
MAP + PlGF 0.785 (0.700–0.869) 31.3 (6.3–50.0) 37.5 (18.8–62.5) 0.797 (0.659–0.936) 35.7 (14.3–64.3) 42.9 (21.4–71.4) 0.904
MAP + UtA-PI 0.803 (0.721–0.885) 25.0 (6.3–50.0) 37.5 (18.8–62.5) 0.766 (0.605–0.926) 35.7 (14.3–64.3) 50.0 (21.4–78.6) 0.712
PAPP-A + PlGF 0.746 (0.637–0.855) 12.5 (0–43.8) 43.8 (18.8–68.8) 0.745 (0.603–0.886) 35.7 (14.3–64.3) 35.7 (14.3–64.3) 0.992
MAP + PAPP-A 0.741 (0.625–0.857) 31.3 (6.3–56.3) 43.8 (18.8–68.8) 0.754 (0.612–0.896) 14.3 (0–42.9) 28.6 (7.1–57.1) 0.901
UtA-PI + PAPP-A 0.767 (0.627–0.907) 37.5 (12.5–68.8) 56.3 (31.3–81.3) 0.751 (0.610–0.892) 28.6 (7.1–57.1) 50.0 (29.9–78.6) 0.877
MAP + UtA-PI + PAPP-A 0.815 (0.726–0.905) 31.3 (12.5–56.3) 43.8 (18.8–68.8) 0.783 (0.624–0.942) 35.7 (14.3–57.1) 57.1 (28.6–85.7) 0.744
MAP + UtA-PI + PlGF 0.830 (0.760–0.899) 18.8 (0–37.7) 43.8 (18.8–68.8) 0.804 (0.649–0.958) 42.9 (14.3–71.4) 57.1 (28.6–85.7) 0.785
MAP + PAPP-A + PlGF 0.793 (0.709–0.877) 31.3 (12.5–56.3) 43.8 (18.8–68.8) 0.803 (0.665–0.942) 35.7 (14.3–64.3) 50.0 (21.4–78.6) 0.919
UtA-PI + PlGF + PAPP-A 0.789 (0.683–0.894) 25.0 (6.3–43.8) 37.5 (12.5–62.5) 0.764 (0.621–0.907) 42.9 (14.3–71.4) 50.0 (29.9–78.6) 0.805
MAP + UtA-PI + PlGF + PAPP-A 0.818 (0.713–0.924) 31.3 (6.3–50.0) 50.0 (25.0–81.3) 0.820 (0.669–0.971) 42.9 (14.3–71.4) 57.1 (28.6–85.7) 0.983
*Comparison between AUCs was by two-tailed P-value. FPR, false-positive rate; MAP, mean arterial pressure; UtA-PI, uterine artery
pulsatility index.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 84–90.
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